Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia

Summary

The purpose of this study is to assess safety and efficacy of CAT-2003 in patients with chylomicronemia. The study will evaluate the effects of CAT-2003 on fasting total and chylomicron triglyceride levels, as well as postprandial total and chylomicron triglyceride clearance. This is a single-blind study. All patients will receive placebo for 1 week, and CAT-2003 for 12 weeks during the 13 week treatment period.

Timeline

Start

2014-03

Primary completion

2015-04

Completion

2015-04

Drugs

Indications